HLA-DR 与 CD117 (c-Kit) 表达的相关性研究：其在急性髓系白血病患者中的预后和治疗反应,Pharmacogenomics and Personalized Medicine

当前位置： X-MOL 学术 › Pharmacogenomics Pers. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

HLA-DR 与 CD117 (c-Kit) 表达的相关性研究：其在急性髓系白血病患者中的预后和治疗反应
Pharmacogenomics and Personalized Medicine ( IF 1.8 ) Pub Date : 2021-03-30 , DOI: 10.2147/pgpm.s268986
Yomna M El-Meligui ₁ , Heba E Abd Elrhman ₂ , Ahmad Salahuddin ₃ , Manal Ali Hamouda ₄ , Amira B Kassem ₅

Affiliation

简介：急性髓性白血病（AML）是成人中最常见的急性白血病类型。HLA-DR 和 CD117 (c-Kit) 是 AML 的重要诊断标志物。我们的目标是确定新诊断的 AML 患者中 HLA-DR 和 CD117 表达的预后意义，并确定 HLA-DR 和 CD117 表达与其他预后标志物（如细胞遗传学异常、FLT3-ITD、对治疗的反应和患者的反应）之间的相关性生存。
方法：本研究包括 100 名新诊断的 AML 患者。所有患者均进行临床、形态学、细胞化学、细胞遗传学分析，分子遗传学分析检测FLT3-ITD，流式细胞仪检测HLA-DR、CD117、CD 34。
结果：结果显示75例患者（77.3%）中发现HLA-DR表达，而在63例患者（64.9%）中发现CD117表达。HLA-DR 表达患者的平均 Hb 浓度显着升高，血小板计数显着升高，与 AML-FAB 亚型（M0、M1 和 M2）、CD34 表达和有利的细胞遗传学组相关。M3 亚型与 HLA-DR-ve 显着相关。而具有CD117表达的患者血小板计数显着降低。双阳性患者（HLA-DR+ve/CD117+ve）与中间细胞遗传学组显着相关，而双阴性患者（HLA-DR-ve/CD117-ve）与有利和中间细胞遗传学组相关，并且阳性（HLA-DR+ve /CD117-ve 或 HLA-DR-ve/CD117+ve）与不良细胞遗传学组相关。
结论：目前的研究表明，CD117 和 HLA-DR 的表达可能是 AML 的预后标志物，因为它们与 M0、M1 和 M2 FAB 亚型相关；此外，HLA-DR和CD117联合阳性表达的患者与CD34表达和中间细胞遗传学组相关。

关键词：急性髓性白血病，HLA-DR，CD117，CD34，FLT3-ITD，反应，细胞遗传学

"点击查看英文标题和摘要"

Correlation Study on HLA-DR and CD117 (c-Kit) Expressions: Its Prognosis and Treatment Response in Acute Myeloid Leukemia Patients

Introduction: Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. HLA-DR and CD117 (c-Kit) are important diagnostic markers of AML. Our objective is to determine the prognostic significance of HLA-DR and CD117 expressions in newly diagnosed AML patients and determine the correlation between HLA-DR and CD117 expressions and other prognostic markers such as cytogenetic abnormalities, FLT3-ITD, response to treatment, and patient’s survival.
Methods: This study included 100 newly diagnosed AML patients. All patients were subjected to clinical, morphological, cytochemical, cytogenetic analysis, molecular genetic analysis to detect FLT3-ITD, and Flowcytometric detection of HLA-DR, CD117, and CD 34.
Results: The results showed that HLA-DR expression was found in 75 patients (77.3%), while CD117 expression was found in 63 patients (64.9%). Patients with HLA-DR expression showed significantly higher mean Hb concentration, significantly higher platelet count, associated with AML-FAB subtypes (M0, M1, and M2), CD34 expression, and favorable cytogenetic group. M3 subtype was significantly associated with HLA-DR-ve. While patients with CD117 expression showed significantly lower platelets count. Double positive patients (HLA-DR+ve/CD117+ve) showed significant association with the intermediate cytogenetic group, while double-negative patients (HLA-DR-ve/CD117-ve) were associated with the favorable and intermediate cytogenetic group and either positive (HLA-DR+ve /CD117-ve or HLA-DR-ve/CD117+ve) associated with poor cytogenetic groups. FLT3-ITD expression had significantly worse overall survival.
Conclusion: The current study suggested that the expression of CD117 and HLA-DR may be a prognostic marker in AML, as they are associated with M0, M1, and M2 FAB subtypes; moreover, patients with combined HLA-DR and CD117 positive expression are associated with CD34 expression and intermediate cytogenetic group.

Keywords: acute myeloid leukemia, HLA-DR, CD117, CD34, FLT3-ITD, response, cytogenetic

更新日期：2021-04-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文